

# RGX-202, an Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy: Interim Clinical Data




Steve Pakola<sup>1</sup>, Amy Harper<sup>2</sup>, Susan Iannaccone<sup>3</sup>, Nancy Kuntz<sup>4</sup>, Carolina Tesi-Rocha<sup>5</sup>, Aravindhan Veerapandiyan<sup>6</sup>, Dawn Phillips<sup>1</sup>, Catherine Wilson<sup>1</sup>, Nidal Boulos<sup>1</sup>, Elisa Tsao<sup>1</sup>, Michelle Gilmore<sup>1</sup>, Stacey Curtiss<sup>1</sup>, Hiren Patel<sup>1</sup>, Michele Fiscella<sup>1</sup>, Olivier Danos<sup>1</sup>, Jahannaz Dastgir<sup>1</sup>

<sup>1</sup>REGENXBIO Inc., Rockville, MD; <sup>2</sup>Children's Hospital of Richmond at Virginia Commonwealth University, Richmond, VA; <sup>3</sup>The University of Texas Southwestern Medical Center, Dallas, TX; <sup>4</sup>Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL; <sup>5</sup>Stanford School of Medicine, Palo Alto, CA; <sup>6</sup>Arkansas Children's Hospital, Little Rock, AR

## Introduction

### Multiple Factors Contribute to Safety and Efficacy in a Gene Therapy Program

#### RGX-202 Therapeutic Approach



### RGX-202 is the Only Microdystrophin Gene Therapy with the Functional Elements of the C-Terminal (CT) Domain Found in Naturally Occurring Dystrophin

